Moebius Medical

Company Overview

Snapshot

Founded in August 2008 by Yaniv Dolev and Nava Zisapel, Moebius Medical operates with 1–10 employees. The company has secured funding across one round from investors including RAD BioMed and Pix Vine Capital. In September 2024, the company's lead product, MM-II, received Fast Track Designation for osteoarthritis knee pain.

Business overview

Moebius Medical is a clinical-stage biotechnology company focused on developing novel pain-relief treatments for osteoarthritis. Its core product, MM-II, is a patent-protected intra-articular biolubricant injection designed to reduce pain and prevent joint damage in patients with mild to moderate symptomatic knee osteoarthritis. The company operates within the Health Tech & Life Sciences sector, specifically in Pharmaceuticals, targeting patients and pharmaceutical companies.

Strategic signal

In September 2024, Moebius Medical's lead product, MM-II, received. This designation, granted in collaboration with Sun Pharma, signals regulatory validation and potential for accelerated development and review, indicating strong market potential and a faster path to commercialization for a critical pain management solution.

Company Intelligence Q&A

What is Moebius Medical's primary focus?

Moebius Medical is a clinical-stage biotechnology company developing novel pain-relief treatments for osteoarthritis.

What is the status of MM-II, Moebius Medical's lead product?

In September 2024, MM-II received Fast Track Designation for osteoarthritis knee pain. Previously, in December 2020, the FDA cleared the company's Investigational New Drug application to initiate a global multi-center phase IIb clinical trial for MM-II.

When did Moebius Medical secure its funding round?

Moebius Medical secured a Seed funding round in August 2008 from investors including RAD BioMed.

What strategic partnership does Moebius Medical have for MM-II?

In December 2016, Sun Pharma and Moebius Medical entered into an exclusive worldwide licensing deal for the further development of MM-II. Moebius Medical handles preclinical studies and product development through Phase 2, while Sun Pharma manages clinical studies, regulatory submissions, and commercialization.

What recent publications has Moebius Medical announced?

In April 2025, Sun Pharma and Moebius Medical announced dual publications on MM-II's Phase 2b clinical trial results and its mechanism of action in osteoarthritis and cartilage.